These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9769027)

  • 1. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials.
    Mielke R; Möller HJ; Erkinjuntti T; Rosenkranz B; Rother M; Kittner B
    Alzheimer Dis Assoc Disord; 1998; 12 Suppl 2():S29-35. PubMed ID: 9769027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials.
    Rother M; Erkinjuntti T; Roessner M; Kittner B; Marcusson J; Karlsson I
    Dement Geriatr Cogn Disord; 1998 Jul; 9 Suppl 1():36-43. PubMed ID: 9716243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.
    Marcusson J; Rother M; Kittner B; Rössner M; Smith RJ; Babic T; Folnegovic-Smalc V; Möller HJ; Labs KH
    Dement Geriatr Cogn Disord; 1997; 8(5):320-8. PubMed ID: 9298634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies.
    Saletu B; Möller HJ; Grünberger J; Deutsch H; Rössner M
    Neuropsychobiology; 1990-1991; 24(4):173-84. PubMed ID: 2135708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials in dementia with propentofylline.
    Kittner B; Rössner M; Rother M
    Ann N Y Acad Sci; 1997 Sep; 826():307-16. PubMed ID: 9329701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propentofylline for dementia.
    Frampton M; Harvey RJ; Kirchner V
    Cochrane Database Syst Rev; 2003; (2):CD002853. PubMed ID: 12804440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group.
    Kittner B
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S166-71. PubMed ID: 10609697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo-controlled trial of the xanthine derivative propentofylline in dementia.
    Möller HJ; Maurer I; Saletu B
    Pharmacopsychiatry; 1994 Jul; 27(4):159-65. PubMed ID: 7972348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic impact of introducing propentofylline for the treatment of dementia in Sweden.
    Wimo A; Witthaus E; Rother M; Winblad B
    Clin Ther; 1998; 20(3):552-66; discussion 550-1. PubMed ID: 9663370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities.
    Bachynsky J; McCracken P; Lier D; Alloul K; Jacobs P
    Alzheimer Dis Assoc Disord; 2000; 14(2):102-11. PubMed ID: 10850749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia.
    Mielke R; Kittner B; Ghaemi M; Kessler J; Szelies B; Herholz K; Heiss WD
    J Neurol Sci; 1996 Sep; 141(1-2):59-64. PubMed ID: 8880694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type.
    Rother M; Kittner B; Rudolphi K; Rössner M; Labs KH
    Ann N Y Acad Sci; 1996 Jan; 777():404-9. PubMed ID: 8624121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromodulatory effect of propentofylline on rat brain under acute and long-term hypoperfusion.
    Plaschke K; Grant M; Weigand MA; Züchner J; Martin E; Bardenheuer HJ
    Br J Pharmacol; 2001 May; 133(1):107-16. PubMed ID: 11325800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propentofylline enhances cerebral metabolic response to auditory memory stimulation in Alzheimer's disease.
    Mielke R; Ghaemi M; Kessler J; Kittner B; Szelies B; Herholz K; Heiss WD
    J Neurol Sci; 1998 Jan; 154(1):76-82. PubMed ID: 9543326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia.
    Ringheim GE
    Ann N Y Acad Sci; 2000 Apr; 903():529-34. PubMed ID: 10818548
    [No Abstract]   [Full Text] [Related]  

  • 19. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
    Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D
    Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.